Latest Conference Articles

September 29th 2019, 9:36pm

ESMO Congress

The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.

September 29th 2019, 8:45pm

ESMO Congress

An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.

September 29th 2019, 8:16pm

ESMO Congress

The addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy.

September 29th 2019, 7:30pm

ESMO Congress

With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.

September 29th 2019, 6:59pm

ESMO Congress

Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.

September 29th 2019, 6:52pm

ESMO Congress

The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

September 29th 2019, 6:35pm

ESMO Congress

Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.

September 29th 2019, 4:23pm

ESMO Congress

The investigational CDK4/6 inhibitor trilaciclib unexpectedly improved survival in metastatic triple-negative breast cancer despite failing to meet a safety-related primary endpoint.

September 28th 2019, 10:30pm

ESMO Congress

A numerical improvement in overall survival was realized with the addition of atezolizumab (Tecentriq) to ado-trastuzumab emtansine (T-DM1; Kadcyla) compared with T-DM1 alone.

September 28th 2019, 9:45pm

ESMO Congress

Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

September 28th 2019, 9:42pm

ESMO Congress

Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.

September 28th 2019, 8:58pm

ESMO Congress

More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).

September 28th 2019, 8:12pm

ESMO Congress

Sacituzumab govitecan demonstrated clinical activity with an overall response rate of 29% in patients with heavily pretreated metastatic urothelial carcinoma.

September 28th 2019, 6:45pm

ESMO Congress

Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer.

September 28th 2019, 6:40pm

ESMO Congress

The first-line combination of nivolumab and ipilimumab led to a clinically meaningful improvement in overall survival versus chemotherapy in patients with advanced non–small cell lung cancer, regardless of PD-L1 expression.

September 28th 2019, 6:39pm

ESMO Congress

Frontline maintenance therapy with the PARP inhibitor niraparib improved median progression-free survival by 5.6 months compared with placebo for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy.

September 28th 2019, 6:35pm

ESMO Congress

Frontline treatment with osimertinib improved median overall survival by 6.8 months compared with erlotinib or gefitinib for patients with metastatic, EGFR-mutant non–small cell lung cancer.

September 28th 2019, 6:32pm

ESMO Congress

The frontline combination of veliparib, carboplatin, and paclitaxel followed by maintenance veliparib monotherapy led to a 32% reduction in the risk of progression or death compared with placebo plus chemotherapy with placebo maintenance for patients with high-grade serous ovarian cancer.

September 28th 2019, 6:26pm

ESMO Congress

Adding the investigational glutaminase inhibitor telaglenastat to everolimus extends progression-free survival compared with everolimus alone in patients with heavily pretreated advanced renal cell carcinoma.

September 28th 2019, 5:29pm

ESMO Congress

The combination of cediranib and olaparib improved progression-free survival in patients with platinum-resistant ovarian cancer, although the difference from chemotherapy did not achieve statistical significance.